Pneumococcal diagnosis and serotypes in childhood community-acquired pneumonia by Elemraid MA et al.
 Newcastle University ePrints 
 
Elemraid MA, Sails AD, Thomas MF, Rushton SP, Perry JD, Eltringham GJA, 
Spencer DA, Eastham KM, Hampton F, Gennery AR, Clark JE, North East of 
England Paediatric Respiratory Infection Study Group. 
Pneumococcal diagnosis and serotypes in childhood community-acquired 
pneumonia.  
Diagnostic Microbiology and Infectious Disease 2013, 76(2), 129-132. 
 
Copyright: 
© 2013 Elsevier Inc. 
Open access under CC BY-NC-ND license 
Link to published article: 
http://dx.doi.org/10.1016/j.diagmicrobio.2013.02.012 
 
Date deposited:  5th January 2015 
 
 
 
This work is licensed under a  
Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License 
 
 ePrints – Newcastle University ePrints 
http://eprint.ncl.ac.uk 
 
Diagnostic Microbiology and Infectious Disease 76 (2013) 129–132
Contents lists available at SciVerse ScienceDirect
Diagnostic Microbiology and Infectious Disease
j ourna l homepage: www.e lsev ie r .com/ locate /d iagmicrob ioPneumococcal diagnosis and serotypes in childhood community-acquired
pneumonia☆,☆☆
Mohamed A. Elemraid a,b,⁎, Andrew D. Sails c, Matthew F. Thomas d,e, Stephen P. Rushton e, John D. Perry f,
Gary J.A. Eltringham c, David A. Spencer d, Katherine M. Eastham g, Fiona Hampton h,
Andrew R. Gennery a,b, Julia E. Clark a,b
and On behalf of the North East of England Paediatric Respiratory Infection Study Group
a Department of Paediatric Infectious Disease and Immunology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK
b Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne NE1 7RU, UK
c Health Protection Agency Public Health Laboratory Newcastle, Royal Victoria Infirmary, Newcastle upon Tyne N1 4LP, UK
d Department of Respiratory Paediatrics, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK
e School of Biology, Newcastle University, Newcastle upon Tyne NE1 7RU, UK
f Department of Microbiology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK
g Department of Paediatrics, Sunderland Royal Hospital, Sunderland SR4 7TP, UK
h Department of Paediatrics, James Cook University Hospital, Middlesbrough TS4 3BW, UK☆ Conflicts of interest and source of funding: This st
from Pfizer Vaccines UK (No. 0887X1-4479). JEC and
research support from Pfizer. The sponsor had no ro
collection, analysis or interpretation, and writing of the
☆☆ Contributors: JEC, ADS and DAS developed the
collected and managed the data. ADS, JDP, GJAE and M
analyses. All authors were involved in the interpretatio
this article.
⁎ Corresponding author. Tel.: +44-0-191-282-1343;
E-mail address: mohamed.elemraid@ncl.ac.uk (M.A
0732-8893 © 2013 Elsevier Inc.
http://dx.doi.org/10.1016/j.diagmicrobio.2013.02.012
Open access under CC BYa b s t r a c ta r t i c l e i n f oArticle history:
Received 29 October 2012
Received in revised form 12 February 2013
Accepted 19 February 2013
Available online 26 March 2013
Keywords:
Diagnosis
Paediatrics
Pneumococcal conjugate vaccine
Pneumonia
Serotype
Streptococcus pneumoniae
Urinary pneumococcal antigenThe 7-valent pneumococcal conjugate vaccine (PCV7) was introduced routinely in the UK from September
2006 and replaced by PCV13 in 2010. In a prospective study from 2009 to 2011 of 160 children aged≤16 years
with radiologically confirmed pneumonia, likely pneumococcal infections were identified in 26%. Detection of
pneumococci was improved with polymerase chain reaction compared to culture (21.6% versus 6% of children
tested, P = 0.0004). Where serotyping was possible, all (n = 23) were non-PCV7 but PCV13 serotypes; 1
(43.5%), 3 (21.7%), 7A/F, and 19A (17.4% each).udy was supported by a grant
DAS received unconditional
le in the study design, data
manuscript.
original study concept. MAE
AE performed the laboratory
n of the results and writing of
fax: +44-0-191-282-4724.
. Elemraid).
-NC-ND license.© 2013 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Streptococcus pneumoniae is the leading bacterial cause of
paediatric community-acquired pneumonia (PCAP) (Rudan et al.,
2008). The 7-valent pneumococcal conjugate vaccine (PCV7) (sero-
types 4, 6B, 9V, 14, 18C, 19F, and 23F) was added into the UK
immunisation schedule from September 2006; subsequently replaced
by PCV13 from April 2010 (additional serotypes 1, 3, 5, 6A, 7F, and19A). Three vaccine doses are administered at the age of 2, 4, and 13
months. When the vaccine was introduced, a catch up programme
was offered to all children born between September 2004 and
September 2006. This vaccination programme would thus be
expected to impact upon the pneumococcal serotypes implicated
in PCAP.
Pathogens are difficult to identify in children with pneumonia,
with blood culture and serological testing often negative due to
minimal presence of bacteremia (Brent et al., 2006; Korppi et al.,
2008). This paucity of S. pneumoniae isolation makes examining
pneumococcal serotype distribution in PCAP difficult, with no UK,
and little worldwide, data. Using non-culture techniques including
pneumococcal detection by polymerase chain reaction (PCR) in
blood (Resti et al., 2010) and pleural fluid (Strachan et al., 2012),
pneumococcal antigen detection in urine (Charkaluk et al., 2006),
and pneumococcal serotype detection by PCR (Esposito et al.,
2012; Resti et al., 2010), we sought to determine the contribution
of S. pneumoniae and specific serotypes to the aetiology of PCAP.
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Now as being indicative of invasive pneumococcal infection for
several reasons. It has good sensitivity (100%) and specificity (56%) in
children with suspected pneumococcal disease (Charkaluk et al.,
2006), but is confounded as a diagnostic test by nasopharyngeal
carriage where up to 21% may be positive (Hamer et al., 2002).
Urinary pneumococcal antigen may also be positive in 4% healthy
nasopharyngeal culture-negative children (Hamer et al., 2002),
although given the increased sensitivity of PCR compared to culture,
it is likely that nasopharyngeal culture-negative children would have
pneumococcal carriage if tested by PCR (Turner et al., 2011). Thus, a
positive urinary antigen in a child with pneumonia and no
pneumococcal nasopharyngeal carriage by PCR is likely to reflect
invasive pneumococcal disease.
2. Materials and methods
2.1. Study population
From October 2009 to March 2011 children aged ≤16 years old
with clinical and radiological features suggestive of pneumonia
admitted to any of three hospitals in North East England were
prospectively enrolled. Informed consent was obtained from parents
and assent from older children. Ethical and Caldicott approvals were
granted (Newcastle and North Tyneside Research Ethics Committee
(No: 08/H0906/105), and Research Approval Board at South Tees
Hospitals NHS Trust (No: 2008075)).
Pneumonia was defined by signs and symptoms suggestive of
lower respiratory tract infection and chest radiographic findings
consistent with pneumonia as determined initially by the local
paediatrician. Exclusions included being resident outside North East
England, clinical bronchiolitis, hospitalisation in the preceding three
weeks, or normal chest radiograph after review by a radiologist. Chest
radiographs were first reported by local radiologists then reviewed by
a second consultant cardiothoracic radiologist at the regional centre.
Radiographic findings were categorised into lobar, patchy, or perihilar
according toWorld Health Organization criteria (Cherian et al., 2005).
Conjugate pneumococcal vaccination history was ascertained.
2.2. Laboratory procedures
Blood samples were collected for serum, blood culture (BacT/
ALERT®, bioMérieux) and pneumococcal PCR testing. Nasopharyngeal
aspirates (NPA) were obtained from infants, and placed in 0.9%
sodium chloride transport solution. For older children, bacterial
nasopharyngeal swab (NPS) was collected. Expectorated sputum
and tracheobronchial secretions (TBS) (sampled via endotracheal
tube or bronchoalveolar lavage) and pleural fluids were tested when
collected. Secretions were inoculated into plates of Columbia agar
(Oxoid) supplemented with 5% horse blood (CBA) and Oxoid brain-
heart infusion broth with 10% serum (Oxoid). Broths were incubatedTable 1
Laboratory investigations and diagnostic criteria of pneumococcal infection.
Sample Pathogen/antigen
Blood S. pneumoniae
Nasopharyngeal secretions, sputum S. pneumoniae
Tracheobronchial secretions
(endotracheal/bronchoalveolar lavage)
S. pneumoniae
Pleural fluid S. pneumoniae
Pneumococcal antigen
Urine Pneumococcal antigen
a ELISA, enzyme-linked immunosorbent assay.overnight at 37 °C and sub-cultured (10 μL) into CBA plates for
incubation at 37°C in 5% carbon dioxide for 48 hours. Pneumococcal
isolates were identified by standard methods including latex
agglutination and API 32 STREP (bioMérieux). Urine samples were
tested for pneumococcal antigen using Binax NOW (Inverness
Medical Innovations Ltd, Ireland). Not every child had all tests
performed.
Total nucleic acid was extracted from blood, respiratory secretions,
culture-negative pleural fluid, and pneumococcal antigen positive
urine samples for PCR using an EasyMag automated nucleic acid
extraction instrument (bioMérieux) and the resulting nucleic acid
used as template in a S. pneumoniae specific PCR targeting the
pneumolysin gene (and autolysin gene for pleural fluids) (Corless et
al., 2001). Any recovered S. pneumoniae was serotyped using a
multiplexed xMAP immunoassay for detection of serotype-specific S.
pneumoniae antigens (Sheppard et al., 2011). This assay identifies
PCV13-serotypes plus serotype 8.
2.3. Diagnostic criteria for pneumococcal infection and
statistical analysis
S. pneumoniae was considered a definite or probable pathogen
when detected from a sterile site, TBS or urine samples. Pneumococcal
detection in NPA/NPS or sputum was considered a possible pathogen
and likely to represent nasopharyngeal carriage in children (Table 1).
Detection rates of pathogens are expressed as proportions of those
tested. Fisher's exact test was used to compare different detection
methods and odds ratios and 95% confidence intervals were
calculated. Data were analysed using Epi Info™ 7.
3. Results
Of 160 children, 56%weremale and 69% aged b5 years, median age
2.6 years. All received antibiotics, none died. Radiographs showed 61%
lobar consolidation, and 42.5% pleural effusion. Forty (25%) children
had empyema. Based on age, pneumococcal vaccination uptake
among 119 eligible children was 94% (89 had PCV7, 10 PCV13, and
13 received combinations of each) (online supplement). Pneumococci
were detected from any site in 64% of children (103/160). S.
pneumoniaewas identified from nasopharyngeal secretions by culture
in 7% (10/141) and by PCR in 63% (76/121); and from sterile sites in
17.4% (24/138); by culture in 6% (8/132); comparedwith PCR in 21.6%
(21/97), P = 0.0004.
S. pneumoniae was the likely (definite/probable) pathogen in 26%
(39/149); 20.8% (21/101) and 37.5% (18/48) tested among those aged
b5 and ≥5 years respectively. Of the 39 pneumococcal infections, 21
children had empyema. Pneumococcal infections among those who
received PCV7 was 26.5% (22/83), compared to 10.5% (2/19) for those
who either had PCV13 alone or doses of both (P= 0.182). A serotype
was identified in 82% tested (23/28); serotypes 1 (n= 10), 3 (n= 5),
7A/F and 19A (n = 4 each) (Table 2). Apart from two children whoTestsa Diagnosis of causative pathogens
Definite/probable Possible
Culture/real-time PCR Growth/positive –
Culture/real-time PCR – Growth/positive
Culture/real-time PCR Growth/positive –
Culture/real-time PCR Growth/positive –
ELISA Positive –
Binax NOW Positive –
Table 2
Proportions of detected pneumococci and serotype distribution.
Tests Tests, n Positive, n (%) Serotype (n/N, types)a
Overall definite/probable infections 149 39 (26.0) 23/28 1 (n = 10), 3 (n = 5), 7A/F (n = 4), 19A (n = 4)
Blood (total) 136 11 (8.0) 6/6
Culture 126 5 (4.0) 3/3 1, 3, 19A
Pneumolysin real-time PCR 86 7 (8.1) 3/3 3, 19A (n = 2)
Pleural fluid (total) 40 19 (47.5) 17/19
Culture 40 3 (7.5) 3/3 1, 19A (n = 2)
Pneumococcal antigen 30 7 (23.3) 6/6 1 (n = 5), 3
Pneumolysin real-time PCR 30 18 (60.0) 18/18 1 (n = 7), 3 (n = 5), 19A (n = 4), 7A/F and NT (n = 1 each)b
Respiratory secretions (total) 151 82 (54.3) 1/10
Nasopharyngeal culture 141 10 (7.0) 5/10 23B, NT (n = 4)
Tracheobronchial culturec 12 1 (8.3) –
Pneumolysin real-time PCR 121 76 (62.8) –
Urinary pneumococcal antigen 106 30 (28.3) 9/17 1 and 7A/F (n = 4 each), 19A
a N, number of isolates assayed for serotype identification.
b NT, non-typeable.
c Collected via endotracheal tube or bronchoalveolar lavage.
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PCV7 serotypes were either unvaccinated (n=9) or PCV7-vaccinated
(n = 12).
Pneumococcal urinary antigen was not detected in any of the 40
children with nasopharyngeal pneumococcal carriage only (on
culture and/or PCR) and no evidence of likely pneumococcal
infection. Half (15/30) of those with Binax-positive samples also
had S. pneumoniae identified in a sterile site. Of the 17 Binax-positive
urines tested, nine identified pneumococcal serotypes. Four of these
had concordant identification of same serotypes from pleural fluid (2
were serotype 1, one each of serotypes 7A/F and 19A).
4. Discussion
This study provides the first information on serotype distribution
of pneumococcal PCAP in the UK after the routine introduction of the
pneumococcal conjugate vaccine. Its timing towards the end of 3
years of PCV7 and during the first year of PCV13 gives an opportunity
for future evaluation of the aetiology of pneumonia in the same
setting. Non-PCV7 but PCV13 serotypes were the major contributor to
the aetiology of CAP.
We detected likely pneumococcal infection in 26% of children with
PCAP, more than previously described in the UK (Clements et al.,
2000; Drummond et al., 2000). With no association between urinary
pneumococcal antigen and nasopharyngeal pneumococcal carriage in
this study, urinary pneumococcal antigen is likely to indicate a
pathogen than carriage. Diagnosis of pneumococcal infection was
increased considerably when pneumolysin PCR was used (Esposito et
al., 2012; Strachan et al., 2012), improving the detection rate from 6%
by culture alone to 23%. This is similar to the increase (3.8% to 15.4%)
reported in a recent Italian study (Resti et al., 2010). It has recently
been recognised that the pneumolysin gene can be detected in non-
pneumococcal Viridans-group streptococci, particularly S. pseudop-
neumoniae and S. mitis (Carvalho Mda et al., 2007), thus introducing
the possibility of false positivity with pneumococcal PCR. We feel this
is unlikely given the clinical context; serotype identification would
not be affected.
In England and Wales non-PCV7 serotypes are now associated
with invasive pneumococcal disease (Miller et al., 2011), and an
increase in pneumococcal serotype 19A is associated with complicat-
ed pneumonia with empyema (Thomas et al., 2012). The observed
increase in detection of pneumococci in this study is presumably
related to both improved molecular techniques and continued
pneumococcal disease due to replacement with non-PCV7 serotypes.
Although the number of serotyped pneumococcal isolates was low,
with the majority being identified from pleural fluids, none were
covered in PCV7, but are included in PCV13. This is reflected by datafrom the USA on children with empyema, where 98% were non-
PCV7 serotypes (Byington et al., 2010). This suggests that PCV13
could substantially reduce invasive pneumococcal disease (Jefferies
et al., 2011).
In conclusion, non-PCV7 serotypes were the major contributor to
the aetiology of pneumococcal pneumonia in UK children. Continued
surveillance is required to monitor for the emergence of serotype
replacement.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.diagmicrobio.2013.02.012.
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